HeartBeam, Inc. — Form 10-K summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing. HeartBeam is a pre-revenue medical-technology company developing ambulatory ECG products using its 3D vector electrocardiography (VECG) platform. Its products were not FDA-cleared for marketing at year-end.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | None reported | None reported |
| General and administrative expense | $7.354 million | $2.030 million |
| Research and development expense | $5.677 million | $0.255 million |
| Total operating expenses / operating loss | $13.031 million | $2.285 million |
| Net loss | $12.962 million | $4.428 million |
| Net loss per share, basic and diluted | $1.59 | $1.03 |
| Cash and cash equivalents at year-end | $3.594 million | $13.192 million |
| Net cash used in operating activities | $9.948 million | $3.230 million |
| Net cash provided by financing activities | $0.350 million | $16.398 million |
Operating expenses rose by $10.746 million year over year, driven by expanded staffing and public-company costs, and greater product-development spending with LIVMOR and Triple Ring. The 2021 net loss included approximately $2.165 million of interest expense, primarily from accretion of the 2015 convertible notes’ discount; those notes converted to equity in 2021. At December 31, 2022, liabilities were $1.665 million, consisting of accounts payable and accrued expenses; the filing reports no outstanding debt balance at that date. Stockholders’ equity was $2.374 million.
Management and the auditor stated that available cash was insufficient for the next 12 months after issuance of the financial statements, raising substantial doubt about the company’s ability to continue as a going concern. The filing provides no revenue, profitability, or cash-runway guidance that resolves this concern. No meaningful gross or operating margin is available because the company reported no revenue.
Business progress, outlook and material developments
- Products and regulation: HeartBeam AIMI is ECG-analysis software for emergency departments; its 510(k) submission was filed August 15, 2022, and FDA questions and responses remained under review. HeartBeam AIMIGo is a handheld telehealth ECG system. The company planned a 510(k) submission for its initial 3-lead version by Q2 2023, followed by a synthesized 12-lead version. These were plans, not clearances.
- Clinical evidence: In the HIDES study, the company reported 93% accuracy for its ischemia marker versus 71.59% for expert readings, based on 186 recordings from 66 patients. In a 110-patient emergency-department study, the algorithm showed 97% sensitivity and 56% specificity for acute coronary syndrome. A 30-participant usability study reported that 19.5% of 1,845 recordings were rejected for signal quality and needed repeating. These are company-reported study results; the filing does not establish commercial performance or broad clinical validation.
- Development spending and commitments: HeartBeam expensed $1.2 million under its 2022 LIVMOR agreements. Its Triple Ring development agreement totaled approximately $3.0 million; $2.3 million had been expensed by year-end, with additional amounts recorded as payable, prepaid, or accrued.
- Post-year-end financing and acquisition: In February 2023, the company established an at-the-market offering of up to $13.0 million, with a 3% sales commission. It also agreed to sell up to $4.0 million of common stock to Maverick at 75% of the specified VWAP measure; a $0.5 million convertible note was settled in March 2023 through issuance of approximately 0.2 million shares. These arrangements may provide capital but can dilute existing holders; availability and proceeds depend on sales. In February 2023, HeartBeam acquired LIVMOR’s FDA-cleared Halo+ atrial-fibrillation system and related intellectual property; the filing does not state the purchase price.
- Other risks and contingencies: Key risks include FDA review or classification delays, further financing needs and dilution, physician adoption and reimbursement uncertainty, clinical and manufacturing execution, competition, reliance on third-party suppliers and cloud/telecommunications services, and data privacy and cybersecurity. The company reported material weaknesses in financial-reporting controls, including inadequate documentation and review processes, insufficient GAAP expertise, and limited segregation of duties. It reported no material pending legal proceedings and no off-balance-sheet arrangements.
- Bank exposure: The company disclosed that approximately $0.6 million was at Silicon Valley Bank when it failed in March 2023; the Federal Reserve subsequently announced protection for depositors. The company said it did not view the exposure as material after that announcement.
Most important facts for investors to verify
- Current cash, actual cash burn, remaining financing capacity, and whether funds are sufficient to address the stated going-concern uncertainty.
- FDA review outcomes and actual submission or clearance dates for AIMI and AIMIGo, including any changes to intended use or required studies.
- Whether clinical findings are independently replicated and support the proposed product claims, particularly performance outside small or preliminary studies.
- Capital raised under the ATM and Maverick agreements, associated share issuance and pricing, and resulting dilution.
- Costs, integration progress, and commercial plans for the Halo+ acquisition, as well as remaining Triple Ring and other development commitments.
- Progress in remediating the disclosed material weaknesses in internal control over financial reporting.